It’s remarkable to watch Omeros CEO Greg Demopulos and his executive team dissolve into a pool of obfuscation and incompetence when the truth finally arrives.
The company said Monday that the Food and Drug Administration rejected its drug called narsoplimab meant to treat patients with a rare but often-deadly complication of bone marrow transplants. The denial finally revealed what many Omeros critics — myself, included — have known for years. The clinical development of narsoplimab was built on shaky, often nonsensical clinical data and a mountain of misleading statements about FDA agreements.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
